Neuraxis, Inc. (NRXS) - 10-K Filing Summary
Business Context and Reporting Period
Company: Neuraxis, Inc.
Filing Type: Form 10-K (Annual Report)
Period Ended: December 31, 2024
Business Overview: Neuraxis is a medical technology company developing neuromodulation therapies for chronic conditions in children and adults. Its primary commercial product is IB-Stim, an FDA-cleared device for functional abdominal pain associated with IBS in adolescents (ages 8-21). A second product, the Rectal Expulsion Device (RED), received FDA clearance in 2024 for evaluating neuromuscular function in adults with chronic constipation. The company is classified as a "smaller reporting company" and an "emerging growth company."
Key Financial Metrics (Year Ended Dec 31, 2024)
| Metric | 2024 | 2023 |
|---|---|---|
| Net Sales | $2,685,925 | $2,460,049 |
| Gross Profit | $2,323,923 | $2,156,704 |
| Gross Margin | 86.5% | 87.7% |
| Operating Loss | $(7,156,817) | $(6,664,495) |
| Net Loss | $(8,241,501) | $(14,626,683) |
| Cash and Cash Equivalents | $3,696,870 | $78,560 |
| Working Capital | $1,832,858 (Surplus) | $(1,643,058) (Deficit) |
| Short-Term Debt | $154,152 | $148,062 |
| Stockholders' Equity | $2,067,748 | $(1,403,241) |
Material Changes vs. Prior Period
- Revenue Growth: Net sales increased 9.2% to $2.69 million, driven by volume growth from financial assistance programs for uninsured patients.
- Profitability Improvement: Net loss decreased 43.7% to $8.24 million. This improvement was primarily due to the elimination of significant non-cash charges related to debt extinguishment, debt discount amortization, and fair value adjustments on derivatives that occurred in 2023 following the IPO.
- Liquidity Transformation: Cash on hand increased from $78,560 in 2023 to $3.70 million in 2024. This was driven by the issuance of $5.25 million in Series B Preferred Stock and proceeds from convertible notes, which were converted to equity.
- Expense Increases: General and Administrative (G&A) expenses rose 7.5% to $8.95 million due to costs associated with being a public company (legal, insurance, listing fees), headcount expansion, and severance charges.
Guidance, Outlook, Risks, and Unusual Items
- Going Concern: Auditors have expressed substantial doubt about the company's ability to continue as a going concern. Management believes existing cash will only be sufficient to meet operating needs before the end of 2025. Future capital requirements depend on insurance adoption and potential additional financing.
- Outlook: The primary driver for future revenue is the adoption of insurance coverage by commercial carriers. The company is actively pursuing a Category I CPT code for PENFS, expected to be finalized in Q4 2025 and effective January 1, 2026.
- Pipeline: Clinical trials are underway for functional nausea, post-concussion syndrome, chemotherapy-induced nausea, and cyclic vomiting syndrome.
- Internal Controls: The company identified material weaknesses in internal control over financial reporting (ineffective approval processes and contract management) that remain unremediated as of December 31, 2024.
- Legal Proceedings: A pending lawsuit involving RICO Act claims and fraudulent misrepresentation regarding billing practices remains unresolved, though the company believes it has meritorious defenses. A separate patent dispute regarding U.S. Patent No. 10,413,719 is also unresolved.
Investor Verification Checklist
- Cash Runway: Verify the sufficiency of the $3.7 million cash balance against the projected burn rate to confirm the "end of 2025" liquidity timeline.
- Insurance Reimbursement: Monitor the status of the Category I CPT code (64X11) and the number of commercial insurers adopting coverage policies, as this is the critical path to revenue scaling.
- Internal Controls: Review progress on remediating the disclosed material weaknesses in financial reporting controls to ensure future financial statement reliability.
- Series B Preferred Stock: Analyze the terms of the 4.28 million shares of Series B Preferred Stock, including the 8.5% cumulative dividend obligation and conversion caps, to understand potential dilution and cash flow impacts.
- Legal Exposure: Track the status of the pending RICO litigation and the patent dispute to assess potential financial liabilities.